



Agenda

RIFT VALLEY FEVER (RVF) VACCINE DEVELOPMENT, PROGRESS AND CONSTRAINTS

INTERNATIONAL WORKSHOP



GF-TADs

GLOBAL FRAMEWORK FOR THE
PROGRESSIVE CONTROL OF
TRANSBOUNDARY ANIMAL DISEASES

Wednesday, 19 January 2011

09.00 Registration at the entrance of Mexico Room (building D)

Chair morning session: Stephane DeLaRocque

09.45 Welcome on behalf of FAO *Juan Lubroth*
Welcome on behalf of OIE *Francois Diaz*
Introduction round
Goals of the meeting and logistical information *Peter de Leeuw*

10.30 **Coffee break**

11.00 "Set the scene" introductions on RVF *IAEA/FAO/WHO*

11.45 RVF in South Africa: the evolution and outbreaks *Truuske Gerdes*

12.15 Experience with RVF in goats in Egypt* *Samia Ahmed Kamal*

12.30 General discussion morning session

12.45 **Lunch**

Chair afternoon session: James Zingesser

14.00 Strategy for the prevention and control of RVF and expectations from the use of vaccines *Stephane DeLaRocque, Pierre Formenty*

14.30 OIE-relevant activities and standards related to Rift Valley Fever *Francois Diaz*

15.00 RVF and the European Commission* *Ramunas Freigofas*

15.30 **Coffee break**

16.00 RVF and the US Government* *William Wilson*

16.30 View of NGO* *Baptiste Dungo*

17.00 View of the industry* *Barbara Freischem*

17.30 General discussion afternoon session

18.30 **Cocktail in the Aventino Room**

* Preliminary title

Thursday, 20 January 2011

Chair morning second day: Rob Moormann

- 08.30** Development of live attenuated RVF virus vaccines for animal use *George Bettinger*
- 09.00** Update on Clone 13 vaccination trials *Michelle Bouloy*
- 09.30** RVF vaccine and DIVA assay efforts *Stuart Nichol*
- 10.00** Capripoxvirus-vectored recombinant RVF vaccines *David Wallace*
- 10.30** **Coffee break and group photo**
- 11.00** Capripox constructs* *Catherine Cêtre-Sossah*
- 11.30** Protection of sheep against RVF virus with a recombinant sheep pox virus vaccine *Reuben Soi*
- 12.00** Discussion morning session
- 12.30** **Lunch**

Chair afternoon second day: Stuart Nichol

- 14.00** DNA and viral-vectored vaccines for RVF: preclinical development and potential for clinical testing *Alejandro Brun and Sarah Gilbert*
- 14.30** RVF immunity provided by a paramyxovirus vaccine vector *Jeroen Kortekaas*
- 15.00** Protective efficacy of several experimental and commercial vaccines not only against a needle challenge, but also an aerosolized RVF virus challenge in a mouse, sheep, and non-human primate model *Ted Ross*
- 15.30** **Coffee break**
- 16.00** Transcriptionally active VLPs of RVF virus *Friedeman Weber*
- 16.30** A virus-like particle based vaccine technology targeting RVF virus *Ramon Flick*
- 17.00** Discussion afternoon session

* Preliminary title

Friday, 21 January 2011

Chair of the last session: Pierre Formenty

08.30 RVF primate model*

Darci Smith

09.00 Current Status of RVF vaccine development and the way ahead:
opportunities and constraints

Rob Moormann

09.30 General discussion including the role of the international organizations

10.00 **Coffee break**

10.30 Continuation of the general discussion

11.00 Approval of Recommendations

12.00 Closure of the meeting

* Preliminary title